Data from: Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

Zhang S, Mao X, Wang H, Cai F, Xu J

Date Published: May 31, 2016

DOI: http://dx.doi.org/10.5061/dryad.hb34s

 

Files in this package

Content in the Dryad Digital Repository is offered "as is." By downloading files, you agree to the Dryad Terms of Service. To the extent possible under law, the authors have waived all copyright and related or neighboring rights to this data. CC0 (opens a new window) Open Data (opens a new window)

Title Data from: The efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinibalone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Downloaded 45 times
Download data extraction-bmjopen-2016-011714.xlsx (17.63 Kb)
Details View File Details

When using this data, please cite the original publication:

Zhang S, Mao X, Wang H, Cai F, Xu J (2016) Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. BMJ Open 6: e011714. http://dx.doi.org/10.1136/bmjopen-2016-011714

Additionally, please cite the Dryad data package:

Zhang S, Mao X, Wang H, Cai F, Xu J (2016) Data from: Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. Dryad Digital Repository. http://dx.doi.org/10.5061/dryad.hb34s
Cite | Share
Download the data package citation in the following formats:
   RIS (compatible with EndNote, Reference Manager, ProCite, RefWorks)
   BibTex (compatible with BibDesk, LaTeX)

Search for data

Be part of Dryad

We encourage organizations to: